Pavlou H N, Kliridis P A, Panagiotopoulos A A, Goritsas C P, Vassilakos P J
Second Department of Cardiology, St Andreas Patras State Hospital, University of Patras Medical School, Greece.
Angiology. 2002 Nov-Dec;53(6):699-707. doi: 10.1177/000331970205300611.
The purposes of this study were to assess the occurrence of euthyroid sick syndrome in patients with acute myocardial infarction (AMI) or unstable angina (UA), and the relationship with beta-blocker or thrombolytic therapy. Plasma triiodothyronine (T3), reverse T3 (rT3), free T3 (FT3), thyroxine (T4), free T4 (FT4), thyroid-stimulating hormone (TSH), thyroxine-binding globulin (TBG), and albumin (ALB) levels were determined in 95 patients (59 males, 36 females, aged 58.4+/-9) with AMI and 19 patients (13 males, 6 females aged 54.7+/-12.3) with UA for 5 consecutive days from the onset of the acute syndrome and 1 month later. Patients were divided according to beta-blocker therapy and thrombolytic therapy. There was a significant T3 decrease and rT3 increase in all patients during the first 5 days following admission (p < 0.05). FT3 and FT4 remained unchanged during the study. In patients with complicated infarctions, the rT3 increase and the T3 decrease were significantly greater compared to those with uncomplicated infarctions (p<0.03). TSH, T4, TBG, and ALB were significantly (p<0.05) decreased only in complicated infarctions. No differences were observed between patients with or without thrombolysis or patients with or without beta-blocker treatment. The apparent decrease in T3, the increase in rT3 levels and the decreased TSH and T4 levels, show clearly that the euthyroid sick syndrome (low T3) occurs not only in AMI but also in UA. In addition, these hormonal changes are not affected by beta-blocker therapy and thrombolysis does not influence the occurrence of the syndrome. The degree of T3 decrease is proportional to the severity of cardiac damage and may have a possible prognostic value.
本研究旨在评估急性心肌梗死(AMI)或不稳定型心绞痛(UA)患者中甲状腺功能正常的病态综合征的发生情况,以及与β受体阻滞剂或溶栓治疗的关系。对95例AMI患者(59例男性,36例女性,年龄58.4±9岁)和19例UA患者(13例男性,6例女性,年龄54.7±12.3岁)从急性综合征发作起连续5天及1个月后测定血浆三碘甲状腺原氨酸(T3)、反三碘甲状腺原氨酸(rT3)、游离三碘甲状腺原氨酸(FT3)、甲状腺素(T4)、游离甲状腺素(FT4)、促甲状腺激素(TSH)、甲状腺素结合球蛋白(TBG)和白蛋白(ALB)水平。患者根据β受体阻滞剂治疗和溶栓治疗进行分组。入院后的前5天,所有患者的T3均显著降低,rT3升高(p<0.05)。在研究期间,FT3和FT4保持不变。与非复杂性梗死患者相比,复杂性梗死患者的rT3升高和T3降低更为显著(p<0.03)。仅在复杂性梗死患者中,TSH、T4、TBG和ALB显著降低(p<0.05)。溶栓或未溶栓患者以及接受或未接受β受体阻滞剂治疗的患者之间未观察到差异。T3明显降低、rT3水平升高以及TSH和T4水平降低,清楚地表明甲状腺功能正常的病态综合征(低T3)不仅发生在AMI患者中,也发生在UA患者中。此外,这些激素变化不受β受体阻滞剂治疗的影响,溶栓也不影响该综合征的发生。T3降低的程度与心脏损伤的严重程度成正比,可能具有一定的预后价值。